“Exceptional” Approval Could Replace “Accelerated” For Rare Cancer Drugs
Executive Summary
An "exceptional" approval process should be carved out of the accelerated approval program for products targeting rare cancers where there is little likelihood of completing confirmatory trials, members of FDA's Oncologic Drugs Advisory Committee recommended
You may also be interested in...
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting
PDUFA Provides Opportunity For Conditional Approvals, Consumer Groups Say
Consumer groups are advocating the creation of a "conditional" approval authority for FDA through the reauthorization of the Prescription Drug User Fee Act